Previous close | 2.6600 |
Open | 3.5895 |
Bid | 2.7800 x 100 |
Ask | 2.8600 x 100 |
Day's range | 2.3500 - 3.6100 |
52-week range | 2.3500 - 14.4500 |
Volume | |
Avg. volume | 270,725 |
Market cap | 2.547M |
Beta (5Y monthly) | 1.55 |
PE ratio (TTM) | N/A |
EPS (TTM) | -14.5600 |
Earnings date | 09 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 15.47 |
-- Helius Medical and Shepherd Center partner on a study that aims at rehabilitating walking mobility in people recovering from stroke ---- Shepherd Center, a top neurorehabilitation hospital, is the third site in Helius’ U.S. registrational program for Portable Neuromodulation Stimulator (PoNS®) in stroke ---- The single-arm study will evaluate PoNS in treating gait and balance deficits in chronic stroke survivors ---- Regulatory submission seeking marketing authorization for stroke expected in
-- Lovell is an approved supplier to the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD) ---- Over 28,000 cases of multiple sclerosis (MS) are reported to the VA annually -- NEWTOWN, Pa., April 03, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced it has partnered with Lovell Government S
Helius Medical Technologies, Inc. (NASDAQ:HSDT) Q4 2023 Earnings Call Transcript March 28, 2024 Helius Medical Technologies, Inc. beats earnings expectations. Reported EPS is $-1.47, expectations were $-4.05. HSDT isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank […]